Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis

Pulmonary mycoses remain a global threat, causing significant morbidity and mortality. Patients with airways disease, including COPD and bronchiectasis, are at increased risks of pulmonary mycoses and its associated complications. Frequent use of antibiotics and corticosteroids coupled with impaired...

Full description

Bibliographic Details
Main Authors: Pei Yee Tiew, Kai Xian Thng, Sanjay H. Chotirmall
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Journal of Fungi
Subjects:
Online Access:https://www.mdpi.com/2309-608X/8/5/480
_version_ 1797498747685437440
author Pei Yee Tiew
Kai Xian Thng
Sanjay H. Chotirmall
author_facet Pei Yee Tiew
Kai Xian Thng
Sanjay H. Chotirmall
author_sort Pei Yee Tiew
collection DOAJ
description Pulmonary mycoses remain a global threat, causing significant morbidity and mortality. Patients with airways disease, including COPD and bronchiectasis, are at increased risks of pulmonary mycoses and its associated complications. Frequent use of antibiotics and corticosteroids coupled with impaired host defenses predispose patients to fungal colonization and airway persistence, which are associated with negative clinical consequences. Notably, <i>Aspergillus</i> species remain the best-studied fungal pathogen and induce a broad spectrum of clinical manifestations in COPD and bronchiectasis ranging from colonization and sensitization to more invasive disease. Next-generation sequencing (NGS) has gained prominence in the field of respiratory infection, and in some cases is beginning to act as a viable alternative to traditional culture. NGS has revolutionized our understanding of airway microbiota and in particular fungi. In this context, it permits the identification of the previously unculturable, fungal composition, and dynamic change within microbial communities of the airway, including potential roles in chronic respiratory disease. Furthermore, inter-kingdom microbial interactions, including fungi, in conjunction with host immunity have recently been shown to have important clinical roles in COPD and bronchiectasis. In this review, we provide an overview of clinical <i>Aspergillus</i> signatures in COPD and bronchiectasis and cover the current advances in the understanding of the mycobiome in these disease states. The challenges and limitations of NGS will be addressed.
first_indexed 2024-03-10T03:37:47Z
format Article
id doaj.art-919d148987904594aefef804be21971e
institution Directory Open Access Journal
issn 2309-608X
language English
last_indexed 2024-03-10T03:37:47Z
publishDate 2022-05-01
publisher MDPI AG
record_format Article
series Journal of Fungi
spelling doaj.art-919d148987904594aefef804be21971e2023-11-23T11:41:42ZengMDPI AGJournal of Fungi2309-608X2022-05-018548010.3390/jof8050480Clinical <i>Aspergillus</i> Signatures in COPD and BronchiectasisPei Yee Tiew0Kai Xian Thng1Sanjay H. Chotirmall2Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore 168753, SingaporeLee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, SingaporeLee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, SingaporePulmonary mycoses remain a global threat, causing significant morbidity and mortality. Patients with airways disease, including COPD and bronchiectasis, are at increased risks of pulmonary mycoses and its associated complications. Frequent use of antibiotics and corticosteroids coupled with impaired host defenses predispose patients to fungal colonization and airway persistence, which are associated with negative clinical consequences. Notably, <i>Aspergillus</i> species remain the best-studied fungal pathogen and induce a broad spectrum of clinical manifestations in COPD and bronchiectasis ranging from colonization and sensitization to more invasive disease. Next-generation sequencing (NGS) has gained prominence in the field of respiratory infection, and in some cases is beginning to act as a viable alternative to traditional culture. NGS has revolutionized our understanding of airway microbiota and in particular fungi. In this context, it permits the identification of the previously unculturable, fungal composition, and dynamic change within microbial communities of the airway, including potential roles in chronic respiratory disease. Furthermore, inter-kingdom microbial interactions, including fungi, in conjunction with host immunity have recently been shown to have important clinical roles in COPD and bronchiectasis. In this review, we provide an overview of clinical <i>Aspergillus</i> signatures in COPD and bronchiectasis and cover the current advances in the understanding of the mycobiome in these disease states. The challenges and limitations of NGS will be addressed.https://www.mdpi.com/2309-608X/8/5/480mycobiomebronchiectasisCOPDfungi<i>Aspergillus</i>next-generation sequencing
spellingShingle Pei Yee Tiew
Kai Xian Thng
Sanjay H. Chotirmall
Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
Journal of Fungi
mycobiome
bronchiectasis
COPD
fungi
<i>Aspergillus</i>
next-generation sequencing
title Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
title_full Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
title_fullStr Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
title_full_unstemmed Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
title_short Clinical <i>Aspergillus</i> Signatures in COPD and Bronchiectasis
title_sort clinical i aspergillus i signatures in copd and bronchiectasis
topic mycobiome
bronchiectasis
COPD
fungi
<i>Aspergillus</i>
next-generation sequencing
url https://www.mdpi.com/2309-608X/8/5/480
work_keys_str_mv AT peiyeetiew clinicaliaspergillusisignaturesincopdandbronchiectasis
AT kaixianthng clinicaliaspergillusisignaturesincopdandbronchiectasis
AT sanjayhchotirmall clinicaliaspergillusisignaturesincopdandbronchiectasis